Club Drugs

  • Samuel DeMariaJr.


The use of illicit substances in large dance parties (“raves”) and nightclubs has become commonplace globally since the 1990s. Having now dispersed from rave sub-cultures, these drugs are available in college bars, house parties, and at concerts. Given this widespread availability, the “typical” club drug user is harder to classify than it had been in the 1990s. One large survey of New York City nightclub attendees attempted to characterize typical users: [1] 1,914 club-going adults aged 18–29 were sampled, of which 70% reported using club drugs at least once and 22% reported recent use. Men were more likely to abuse ketamine and GHB, while female gender was predictive of cocaine use. Gay/bisexual orientation and White race were predictive of use of several club drugs.


Neuroleptic Malignant Syndrome Malignant Hyperthermia Malignant Hyperthermia Serotonin Syndrome Central Pontine Myelinolysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kelly BC, Parsons JT, Wells BE. Prevalence and predictors of club drug use among club-going young adults in New York City. J Urban Health. 2006;83(5):884–95.PubMedCrossRefGoogle Scholar
  2. 2.
    European Monitoring Centre for Drugs and Drug addiction. The state of the drugs problem in the European Union and Norway: Annual report; 2007.Google Scholar
  3. 3.
    US Department of Heath and Human Services. National survey on drug use and health. Washington, DC: US Department of Health and Human Services; 2005.Google Scholar
  4. 4.
    National Institute on Drug Abuse. The monitoring the future national results on adolescent drug use: overview of key findings, 2001. Ann Arbor, MI: University of Michigan Institute for Social Research; 2002.Google Scholar
  5. 5.
    Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21(12):1486–513.PubMedCrossRefGoogle Scholar
  6. 6.
    Suarez RV, Riemersma R. “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs. 1986;18:291–304.PubMedGoogle Scholar
  8. 8.
    Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs. 1998;30(4):371–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319–27.PubMedGoogle Scholar
  10. 10.
    Wolff K, Hay AWM, Sherlock K, Conner M. Contents of “ecstasy”. Lancet. 1995;346:1100–1.PubMedCrossRefGoogle Scholar
  11. 11.
    Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl). 2000;152:230–48.CrossRefGoogle Scholar
  12. 12.
    Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5:79–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav. 1988;29(2):269–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics. 2004;45:84–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferigolo M, Machado AGS, Oliveira NB, et al. Ecstasy intoxication: the toxicological basis for treatment. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:332–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Cami J, Farre M, Mas M. Human pharmacology of 3,4- methylenedioxymethamphetamine (“Ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455–66.PubMedCrossRefGoogle Scholar
  17. 17.
    Mas M, Farre M, de la Torre R. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–45.PubMedGoogle Scholar
  18. 18.
    Peroutka SJ. Incidence of recreational use of 3,4- methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on an undergraduate campus. N Engl J Med. 1987;317:1542–3.PubMedGoogle Scholar
  19. 19.
    Cohen RS. Subjective reports on the effects of the MDMA (‘Ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1137–45.PubMedCrossRefGoogle Scholar
  20. 20.
    O’Cain PA, Hletko SB, Ogden BA, et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav. 2000;70:141–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Walsh T, Carmichale R, Chestnut J. A hyperthermic reaction to ecstasy. Br J Hosp Med. 1994;51:476.PubMedGoogle Scholar
  22. 22.
    Gill JR, Hayes JA, de Souza IS, et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci. 2002;47:121–6.PubMedGoogle Scholar
  23. 23.
    Logan ASC, Stickle B, O’Keefe N, Hewitson H. Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C. Anaesthesia. 1993;48:1017–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Hall AP. “Ecstasy” and the anaesthetist. Br J Anaesth. 1997;79:697–8.PubMedGoogle Scholar
  25. 25.
    Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with “Ecstasy” and “Eve” misuse. J Clin Pathol. 1996;49:149–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Schmidt CJ, Black CK, Abbate GM, Taylor VL. MDMA induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Nimmo SM, Kennedy BW, Tullett WM, Blyth AS, Dougall JR. Drug-induced hyperthermia. Anaesthesia. 1993;48(10):892–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Benowitz NL. Amphetamines. In: Olson KR, editor. Poisoning and drug overdose. 3rd ed. Stamford, CT: Appleton & Lange; 1999. p. 68–70.Google Scholar
  29. 29.
    Fiege M, Wappler F, Weisshorn R, et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine (“ecstasy”). Anesthesiology. 2003;99:1132–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89(6):1277–96.PubMedCrossRefGoogle Scholar
  31. 31.
    Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.PubMedCrossRefGoogle Scholar
  33. 33.
    Ghuran A, van Der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. BMJ. 2001;323:464–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Brody S, Krause C, Veit R, Rau H. Cardiovascular autonomic dysregulation in users of MDMA (“Ecstasy”). Psychopharmacology. 1998;136:390–3.PubMedCrossRefGoogle Scholar
  35. 35.
    Kessel B. Hyponatraemia after ingestion of “Ecstasy”. BMJ. 1994;308:414.PubMedCrossRefGoogle Scholar
  36. 36.
    Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “Ecstasy” (3,4-MDMA) [letter]. Lancet. 1996;347:1052.PubMedCrossRefGoogle Scholar
  37. 37.
    Henry JA, Fallon JK, Kicman AT. Low-dose MDMA (“Ecstasy”) induces vasopressin secretion [letter]. Lancet. 1998;351:1784.PubMedCrossRefGoogle Scholar
  38. 38.
    Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (“Ecstasy”) usage. J Clin Gastroenterol. 1995;20:244–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229–33.PubMedCrossRefGoogle Scholar
  40. 40.
    Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in Ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129–33.PubMedCrossRefGoogle Scholar
  42. 42.
    Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry. 1993;56(9):1036–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med. 1993;69:874–89.CrossRefGoogle Scholar
  44. 44.
    McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449–54.PubMedCrossRefGoogle Scholar
  45. 45.
    McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Drug Saf. 1996;15:107–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Ranalli E, Bouton R. Intracerebral haemorrhage associated with ingestion of “Ecstasy” [abstr]. Eur Neuropsychopharmacol. 1997;7:S263.CrossRefGoogle Scholar
  47. 47.
    Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Klein M, Kramer F. Rave drugs: pharmacological considerations. AANA J. 2004;72:61–7.PubMedGoogle Scholar
  49. 49.
    Reneman L, Habraken JB, Majoie CB, et al. MDMA (“Ecstasy”) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol. 2000;21:1001–7.PubMedGoogle Scholar
  50. 50.
    Richards JR. Rhabdomyolisis and drugs abuse. J Emerg Med. 2000;19:51–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63:1–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse. 2005;40:1189–201.PubMedCrossRefGoogle Scholar
  54. 54.
    Okun M, Bartfield RB, Doering PL. GHB toxicity: what you need to know. Emerg Med. 2000;10–23.Google Scholar
  55. 55.
    Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid: efficacy, potential abuse and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Halkitis PN, Palamar JJ. GHB use among gay and bisexual men. Addict Behav. 2006;31(11):2135–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Knudsen K, Greter J, Verdicchio M, et al. A severe outburst of GHB poisonings (gamma-hydroxybutyrate, gamma-hydroxybutyric acid) on the West Coast of Sweden. Mortality numbers ahead of heroin. Clin Toxicol. 2006;44(5):637–8.Google Scholar
  58. 58.
    Tunnicliff G. Sites of action of gamma-hydroxybutyrate – a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35(6):581–90.PubMedCrossRefGoogle Scholar
  59. 59.
    Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC, et al. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol. 2000;426(4):549–60.PubMedCrossRefGoogle Scholar
  60. 60.
    Graeme KA. New drugs of abuse. Emerg Med Clin North Am. 2000;18:625–36.PubMedCrossRefGoogle Scholar
  61. 61.
    Galloway GP, Frederick SL, Staggers Jr F. Physical dependence on sodium oxybate. Lancet. 1994;343(8888):57.PubMedCrossRefGoogle Scholar
  62. 62.
    Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23:151–6.PubMedCrossRefGoogle Scholar
  63. 63.
    McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001;33(2):143–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37:147–53.PubMedCrossRefGoogle Scholar
  65. 65.
    Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7:278–81.PubMedCrossRefGoogle Scholar
  66. 66.
    Rome ES. It’s a rave new world: rave culture and illicit drug use in the young. Clev Clin J Med. 2001;68:541–50.CrossRefGoogle Scholar
  67. 67.
    Berti M, Baciarello M, Troglio R, Fanelli G. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets. 2009;10(8):707–15.PubMedCrossRefGoogle Scholar
  68. 68.
    Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs. 2001;33:151–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–93.PubMedGoogle Scholar
  71. 71.
    Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36(2):186–97.PubMedCrossRefGoogle Scholar
  72. 72.
    Weiner AL, Viera L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447–51.PubMedCrossRefGoogle Scholar
  73. 73.
    Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care. 2002;30:382–4.PubMedGoogle Scholar
  74. 74.
    Ricaurtie GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet. 2005;365:2137–45.CrossRefGoogle Scholar
  75. 75.
    Yu Q, Montes S, Larson D, Watson RR. Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci. 1995;75:29–43.Google Scholar
  76. 76.
    National Institute on Drug Abuse, Methamphetamine Abuse and addiction: what is Methamphetamine? Bethesda, MD: National Institute of Health; 1998. NIDA research report series, NIH publication 98-4210.Google Scholar
  77. 77.
    Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377–82.PubMedCrossRefGoogle Scholar
  78. 78.
    Karch SB, Stephens BG, Ho CH. Methamphetamine related deaths in San Francisco; demographic, pathologic and toxicologic profiles. J Forensic Sci. 1999;44:359–68.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of AnesthesiologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations